WhatsApp
backNews Article

Sai Life Sciences Secures Long-Term Credit Rating Upgrade to IND AA from India Ratings

India Ratings upgrades Sai Life Sciences’ long-term bank loan rating to IND AA with Stable Outlook and affirms short-term IND A1+ rating on 13 November 2026

Sai Life Sciences Limited's long-term bank loan rating has been upgraded to 'IND AA' from 'IND AA-' by India Ratings & Research on 13th November 2026, reflecting improved business and financial profile, with affirmed short-term rating at 'IND A1+'. The company plans INR 11 billion to INR 13 billion capex in FY27, supporting future growth amid manageable credit metrics.

6 days ago|SAILIFE+0.41%
Sai Life Sciences LimitedSAILIFECredit Rating

Sai Life Sciences Limited

Credit Rating

Sai Life Sciences Limited's long-term bank loan credit rating was upgraded by India Ratings & Research on 13 November 2026 to 'IND AA' from 'IND AA-', while its short-term rating remained affirmed at 'IND A1+'. This upgrade reflects the company’s stronger business and financial profile backed by growth in contract research and manufacturing segments.

The company’s consolidated bank loan facilities amount to ₹7,690 million. The upgrade anticipates sustained improvement supported by growing contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) businesses, enhanced operating profitability, and comfortable credit metrics despite ongoing capacity-building investments.

Sai Life Sciences demonstrated revenue growth to ₹21,925 million in FY26 from ₹16,946 million in FY25, with EBITDA rising to ₹6,312 million and EBITDA margins improving to 29%. The company’s CRO business contributed 35% and the CDMO segment 65% to revenue in FY26. The company has a diversified client base including 19 of the top 25 global pharmaceutical companies by market capitalization.

The company plans a significant capital expenditure of ₹11 billion to ₹13 billion in FY27 to support the next growth phase, partially funded through internal accruals and new borrowings. This is expected to temporarily elevate net leverage ratios, but profitability and cash generation are expected to remain robust.

India Ratings maintains a Stable Outlook considering the company’s ability to sustain profitability and manage leverage amid planned investments, with key monitoring points including timely commissioning and ramp-up of expanded capacities and improvement in asset utilization.

Highlights

  • India Ratings upgraded Sai Life Sciences’ long-term bank loan rating from 'IND AA-' to 'IND AA' on 13 November 2026.
  • Short-term rating affirmed at 'IND A1+'.
  • Rated bank loan facilities total ₹7,690 million.
  • FY26 revenue grew to ₹21,925 million with EBITDA of ₹6,312 million and 29% margin.
  • ₹11-13 billion capex planned in FY27 to support growth and capacity expansion.
  • Stable Outlook reflects expectation of sustained business profile and managed leverage despite sizeable investments.

Key Data Snapshot

Date of Credit Rating Upgrade13th November 2026
Rated Bank Loan Limits₹7,690 million
Long-term Rating After UpgradeIND AA/Stable
Previous Long-term RatingIND AA-/Positive
Short-term RatingIND A1+ (Affirmed)
FY26 Consolidated Revenue₹21,925 million
FY26 Consolidated EBITDA₹6,312 million
FY26 EBITDA Margin29%
FY27 Planned Capital Expenditure₹11 billion to ₹13 billion
Interest Coverage Ratio FY2616.1x
Adjusted Net Leverage FY260.2x

What happened

  • India Ratings & Research upgraded Sai Life Sciences' long-term bank loan rating to 'IND AA' from 'IND AA-' on 13 November 2026 and affirmed its short-term rating at 'IND A1+'.
  • The bank loan facilities rated total ₹7,690 million.
  • The rating upgrade reflects an improved business and financial profile and a stable outlook.

Key details

  • FY26 consolidated revenue increased to ₹21,925 million from ₹16,946 million in FY25, driven by growth in both CRO and CDMO segments.
  • EBITDA improved to ₹6,312 million in FY26 with a margin of 29%, up from 24% in FY25.
  • The company’s CRO business contributed 35% and the CDMO segment 65% to FY26 revenues.
  • Sai Life Sciences services 19 of the top 25 global pharmaceutical companies by market capitalization.
  • A capital expenditure of ₹11-13 billion is planned for FY27 to expand capacity and capability, with ₹6.2 billion already spent by 1HFY27.
  • The capex is funded by internal accruals and incremental borrowings, expected to moderate credit metrics but keep them within a comfortable range.
  • Stable Outlook assumes timely commissioning and ramp-up of capacity expansions and sustained profitability.

Financial performance

  • Interest coverage ratio improved to 16.1x in FY26 from 5.3x in FY25.
  • Adjusted net leverage stood at 0.2x in FY26, remaining comfortable despite planned capex.

More News on Credit Rating

View all

Latest corporate announcements and market updates in Credit Rating.

View all news
Sai Life Sciences Secures Long-Term Credit Rating | Stockk News